HGMD is the leading content knowledgebase for interpretation of genomic data in hereditary and rare diseases, providing a deep resource of expertly curated data from the world’s scientific and clinical literature. The 100,000 Genomes Project will use QIAGEN’s HGMD Online Professional solution, which is part of the QIAGEN Clinical Insight portfolio of solutions for the interpretation of complex genomic data, to support scientists, clinicians and researchers in 13 NHS Genomic Medicine Centres for clinical reporting and interpretation.
Category: Biotech
European Bioinformatics Institute And Collaborate To Enhance Global…
Red Hat, Inc. , the world’s leading provider of open source solutions, today announced that the European Bioinformatics Institute , part of the European Molecular Biology Laboratory, is using Red Hat OpenStack Platform to deliver the scale and flexibility required to drive its Embassy Cloud project. The goal of Embassy Cloud is to transform the way collaborative research, such as pan-cancer analysis, tackles the world’s toughest biological challenges.
Stem cell secretions may protect against glaucoma
A new study in rats shows that stem cell secretions, called exosomes, appear to protect cells in the retina, the light-sensitive tissue in the back of the eye. The findings, published in Stem Cells Translational Medicine , point to potential therapies for glaucoma, a leading cause of blindness in the United States.
A 700k lift for industrial biotech
A string of Scottish businesses and universities and are set for a boost after the Industrial Biotechnology Innovation Centre earmarked more than 700,000 of investment for micro-enterprises specialising in industrial biotech. Spread across five projects, the funding will aid research in areas such as new and environmentally-friendly protein production, new tools for vaccines and therapies, processes to increase the value of seaweed crops, bioprocessing and natural pigment production.
J&J to buy Actelion for $30-billion, spin off R&D unit
This file photo shows the exterior of the headquarters of Swiss biotechnology group Actelion in Allschwil, near Basel. U.S. pharmaceuticals giant Johnson & Johnson on Jan. 26 announced it was buying Swiss medical firm Actelion for $30-billion.
Planning bioinformatics workflows using an expert system.
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Bioinformatic analyses are becoming formidably more complex due to the increasing number of steps required to process the data, as well as the proliferation of methods that can be used in each step.
Biotech ETFs can Cope With the new White House
The healthcare sector was a laggard last year, but the iShares Nasdaq Biotechnology ETF , SPDR S&P Biotech ETF and other biotechnology exchange traded funds are shaking out of that slumber with some solid gains in 2017’s early stages.
Novavax Inc. (NVAX) Stock Rating Reaffirmed by Cantor Fitzgerald
‘s stock had its “hold” rating restated by research analysts at Cantor Fitzgerald in a research report issued on Friday. They currently have a $2.00 price objective on the biopharmaceutical company’s stock.
FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Notes into shares
Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy and Bracknor Investment the Company’s board of directors has January 20, 2017 resolved to approve Bracknor’s request relating to the funding programme to convert EUR 50,000 worth of Convertible Notes into the Company’s K shares. Due to the conversion of the Convertible Notes, the Company issues 741,784 new K shares in the Company to Bracknor with the conversion price of EUR 0.067405 per share.
Why are Americans wary of advances in biotechnology?
We are truly living in a remarkable era of biotechnological progress. Emerging nanotechnologies and immunotherapies offer the possibility of the targeted destruction of cancerous cells.
Danish food giants and DTU researchers come together to solve the ‘ingredients paradox’
‘DTU has a long tradition for researching in the fields of biotechnology and process technology with an innovative slant. We are continuing to build on this tradition,’ said hansen.
CEG’s Kennedy says Capital Region ready for biotech push
Richard Honen of Phillips Lyle, right, accepts the JeffreyA. Lawrence Lifetime Contributor award from Andrew Kennedy, president and CEO of Center for Economic Growth during CEG’s annual awards luncheon at the Desmond Hotel on Thursday, June 23, 2016 in Colonie, N.Y. Kennedy says the Capital Region’s biotech sector has promise.
Athersys Subsidiary and Leading Animal Health Company Enter Into…
Athersys, Inc. announced today that through its Belgian subsidiary, ReGenesys BVBA , it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area.
India’s first GM food crop held up by lawsuit
India’s long-standing push to approve genetically modified food crops has been controversially delayed, after an environmental campaigner launched a lawsuit that accuses scientists of deceiving the public about the benefits of transgenic mustard. The claims are untrue, says Deepak Pental, a plant geneticist at the University of Delhi who has led research into the crop.
Korea to invest W98.2b in upgrading biopharma evaluation guidelines
The South Korean government said Tuesday that it would invest 98.2 billion won in improving its evaluation guidelines for new biopharmaceutical products over the next 10 years. The plans came as part of the latest agenda set by a special pan-government biotechnology committee led by the Ministry of Science, ICT and Future Planning.
Brokerages Set $6.00 Target Price for Athersys, Inc.
Shares of Athersys, Inc. have earned a consensus broker rating score of 1.00 from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Natera, Inc. (NTRA) Downgraded to Sell at Zacks Investment Research
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.
Fidelity Biotech Fund: Better than the Index?
Of all the Fidelity mutual funds, its healthcare-focused funds have some of the best records. The Fidelity Select Biotechnology Portfolio But there may be more to its performance than meets the eye.
Fidelity Biotech Fund: Better than the Index?
Fidelity Select Biotechnology Fund has crushed the broader market, but doesn’t fare so well when compared to other biotech mutual funds and ETFs. Of all the Fidelity mutual funds, its healthcare-focused funds have some of the best records.
Week in Review: Nasdaq Brushes Aside Trump-Triggered Selloff in Biotech
The Nasdaq ended the week with a record close in four out of five trading days, even when under assault by a selloff in biotech stocks. Despite an assault by a selloff in biotech stocks, the Nasdaq ended the week with a record close in four out of five trading days.
Using 21st Century Science to Improve Risk-Related Evaluations
Over the last decade, several large-scale United States and international programs have been initiated to incorporate advances in molecular and cellular biology, -omics technologies, analytical methods, bioinformatics, and computational tools and methods into the field of toxicology. Similar efforts are being pursued in the field of exposure science with the goals of obtaining more accurate and complete exposure data on individuals and populations for thousands of chemicals over the lifespan; predicting exposures from use data and chemical-property information; and translating exposures between test systems and humans.
Johns Hopkins researchers helping in search for elusive cancer causing genes
A group of scientists at Johns Hopkins University is studying various bioinformatics methods to discover the ones that help identify the genetic mutations that encourage tumor cells to thrive in an effort to develop drugs to fight the cancer. A group of scientists at Johns Hopkins University is studying various bioinformatics methods to discover the ones that help identify the genetic mutations that encourage tumor cells to thrive in an effort to develop drugs to fight the cancer.
U.S. bioengineers develop low-cost, hand-powered blood centrifuge
Bioengineers at Stanford University in west coast of the United States have created an ultra-low-cost, hand-powered blood centrifuge with rotational speeds of up to 125,000 revolutions per minute . The device, capable of separating blood plasma from red cells in 1.5 minutes, applies the same mechanical principles in a whirligig, which is built by threading a loop of twine through two holes in a button, grabbing the loop ends, then rhythmically pulling.
UNC Nobel Laureate Oliver Smithies dies at age 91
Oliver Smithies, D.Phil., who was recruited to North Carolina with grant funding from the North Carolina Biotechnology Center and won the Nobel Prize in Physiology or Medicine 20 years later, died today at the age of 91. In 1987, the Biotechnology Center helped recruit seven researchers from the University of Wisconsin in Madison to start the University of North Carolina at Chapel Hill’s molecular biology and biotechnology research program. The Biotech Center’s faculty recruitment grant program, inaugurated to help attract that group of Wisconsin scientists, was named to honor Smithies after he became a Nobel laureate in 2007.
Drug stocks plunge as Trump threatens to force price bidding
Pharmaceutical and biotech stocks plummeted Wednesday as President-elect Donald Trump said he’d force the industry to bid for government business in order to save the government billions of dollars. “They are getting away with murder.
Biden’s Cancer Moonshot Draws on Aussie Nobel-Winning Expertise
U.S. Vice President Joe Biden arrived in Melbourne last July with his granddaughters in tow. Bypassing sporting stadiums and race-car tracks, Biden’s first official stop in the world’s sporting capital was to open a A$1 billion cancer center.
Lab Automation Market Value Share, Analysis and Segments 2015-2025
Future Market Insights has announced the addition of the “Lab Automation Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering. Laboratory automation system comprises of automated lab instruments, devices and software algorithms which provides benefits such as increased productivity, reduced cycle time, improved workflow coverage and enhanced data quality.
Secretive Biotech Unicorn Moderna Unveils Pipeline, Financials
Moderna Therapeutics Inc., one of the best-funded private biotechnology companies in the U.S., unveiled its long-secret research and development pipeline on Monday, including experimental vaccines, cancer treatments and a cardiovascular therapy. The Cambridge, Massachusetts-based startup has about $1.3 billion in cash on hand from investors, pharmaceutical partners and government grants, according to a presentation Monday at the J.P.Morgan Chase & Co.
Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
Amicus Therapeutics , a global biotechnology company at the forefront of therapies for rare and orphan diseases, today provided its full-year 2017 strategic outlook and financial guidance. “In 2016 we made significant progress in our transformation to a global commercial-stage biotech company while we continued to advance and expand our tremendous pipeline of first- and/or best-in-class medicines for people living with devastating rare diseases,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. “We begin 2017 in an excellent position to develop and deliver great medicines for patients and to create significant shareholder value.
Evotec and Eternygen to Develop Novel Metabolic Disease Therapy
Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH by becoming an investor in addition to being a pre-clinical drug discovery partner. Within a consortium of investors including VC Fonds Technologie Berlin, managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices, Epidarex and Evotec together will participate in Eternygen’s latest funding round of EUR 8 m .
Biotechs are paying a price for their high drug costs
The biotech industry hit a speed bump in 2016 after logging accelerating growth for years. US drug approvals fell to just 22 – from 45 in 2015 – a six-year low.
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .
Protein fold identification using machine learning methods on contact maps
In 2016 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology , pp. 1-6, doi:10.1109/cibcb.2016.7758096 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Former Biogen CEO Scangos to lead Gates-backed biotech in San Francisco
After stepping down as CEO of Cambridge-based Biogen, George Scangos has wasted no time in finding a new job back home in California.
Carlyle Said to Explore Sale of Vitamin Maker Nature’s Bounty
Carlyle Group LP is exploring a sale of nutritional-supplements maker Nature’s Bounty Co., whose brands include “MET-Rx” and “Pure Protein,” people with knowledge of the matter said. The private equity firm has held talks with potential advisers about selling the U.S. company, formerly known as NBTY Inc., according to the people.
Aptose Biosciences to Present at Biotech Showcase 2017 Conference
Aptose Biosciences Inc. , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech ShowcaseTM 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA. The audio webcast will be archived shortly after the live event and will be available through the Aptose website at www.aptose.com .
Cellectar Biosciences to Present at the 9th Annual Biotech Showcase
Cellectar Biosciences, Inc. , an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the Biotech Showcase in San Francisco on January 11, 2017 at 10:00 AM PT in Room 2 . “We look forward to discussing the continued advancement of our lead PDC program, CLR 131, as well as providing relevant updates on our other product candidates and corporate performance,” said Mr. Caruso.
OncoMed Announces Year-End Cash Balance and 2017 Outlook
OncoMed Pharmaceuticals Inc. , a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today pre-announced its 2016 year-end cash balance and reviewed key anticipated events for 2017. OncoMed ended 2016 with approximately $184.6 million in cash.
LG Chem chief renews pledge to boost biopharma business
South Korea’s leading chemicals maker LG Chem is out to boost its newly merged pharmaceutical unit LG Life Sciences, with aims to drive up its competitiveness in the global red biotechnology, or medical biotech, sector. LG Chem Vice Chairman and CEO Park Jin-soo visited LG Life Sciences’ production plant in Iksan, North Jeolla Province on Thursday, marking his first official on-site visit for 2017.